European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the appro

See more here: 
European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain Cancer

Related posts:

1. European CHMP Formally Adopts Negative Opinion On Oncophage(R) Antigenics Inc. (NASDAQ: AGEN) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion...
2. FDA Advisory Committee Recommends Against Approving Tarceva For First-Line Maintenance Use In Advanced Non-Small Cell Lung Cancer OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic...
3. MagForce Nanotechnologies AG Applies For European Regulatory Approval Of Its Nano-Cancer(R) Therapy MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products....
4. Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance For Proposed INTERCEPT Blood System Phase III Trial Design Cerus Corporation (NASDAQ:CERS) announced that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III...
5. Amgen Receives CHMP Positive Opinion For Prolia(TM) (Denosumab) In The European Union Amgen Inc. (Nasdaq: AMGN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization...
6. Ouroboros Medical Inc. Establishes European Approval And Awarded 2009 Spine Technology Summit Award Ouroboros Medical, Inc., an early stage medical device company focused on developing minimally invasive spine products for degenerated disc disease, has received approval to market Ouroboros's spinal fusion product in...
7. World’s First Delivery Of Intra-Arterial Avastin Directly Into Brain Tumor Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. ...
8. FDA Advisory Committee Supports Use Of Aztreonam For Inhalation Solution For Patients With Cystic Fibrosis Gilead Sciences, Inc. (Nasdaq: GILD) announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended that aztreonam for inhalation solution be approved for...
9. Patient Receives World’s First Delivery Of Intra-arterial Avastin Directly Into A Malignant Brain Tumor Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. ...
10. FDA Advisory Committee Finds Data Support The Claim That SPIRIVA(R) HandiHaler(R) Reduces COPD Exacerbations The U.S. ...
11. Basilea’s Toctino(R) Recommended For Approval In 15 Additional European Countries Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that Toctino® (alitretinoin) was recommended for regulatory approval under the Repeat-use Procedure in 13 additional European Union (EU) Member States as well as in...
12. Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung Cancer The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in...
13. Independent Advisory Committee Recommends Continuation Of Phase III Oral Calcitonin Studies For Osteoporosis And Osteoarthritis Unigene Laboratories, Inc. (OTCBB: UGNE) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin...
14. Nanostart-Owned MagForce Nanotechnologies AG: Application Submitted For EU Regulatory Approval Of Nano-Cancer(R) Therapy MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy. The application is based...
15. Gore Receives European CE Mark Approval For Next Generation Conformable GORE TAG(R) Thoracic Endoprosthesis W.L. Gore & Associates (Gore) announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. ...

« Evidence Does Not Connect H1N1 Vaccine To Patient Deaths, WHO Says Geron Presents Interim Clinical Data On Its Telomerase Inhibitor Drug At AACR-NCI-EORTC »